Creasey A - Search Results

1

Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation.

Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L. Johnson K, et al. Among authors: creasey a. J Immunol. 1998 May 15;160(10):5130-5. J Immunol. 1998. PMID: 9590265

2

The proinflammatory cytokine response to coagulation and endotoxin in whole blood.

Johnson K, Aarden L, Choi Y, De Groot E, Creasey A. Johnson K, et al. Among authors: creasey a. Blood. 1996 Jun 15;87(12):5051-60. Blood. 1996. PMID: 8652818 Free article.

3

Soluble IL-2 receptor beta and gamma subunits: ligand binding and cooperativity.

Johnson K, Choi Y, Wu Z, Ciardelli T, Granzow R, Whalen C, Sana T, Pardee G, Smith K, Creasey A. Johnson K, et al. Among authors: creasey a. Eur Cytokine Netw. 1994 Jan-Feb;5(1):23-34. Eur Cytokine Netw. 1994. PMID: 8049354

4

Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.

Johnson K, Zaror I, Bauer D, Choi Y, Creasey A, Innis M. Johnson K, et al. Among authors: creasey a. Thromb Haemost. 1998 Oct;80(4):585-7. Thromb Haemost. 1998. PMID: 9798974

5

Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock.

Goldfarb RD, Glock D, Johnson K, Creasey AA, Carr C, McCarthy RJ, Matushek M, Akhter I, Trenholme G, Parrillo JE. Goldfarb RD, et al. Among authors: creasey aa. Shock. 1998 Oct;10(4):258-64. doi: 10.1097/00024382-199810000-00005. Shock. 1998. PMID: 9788657

6

Tissue factor pathway inhibitor activity in severe sepsis.

Creasey AA, Reinhart K. Creasey AA, et al. Crit Care Med. 2001 Jul;29(7 Suppl):S126-9. doi: 10.1097/00003246-200107001-00038. Crit Care Med. 2001. PMID: 11445747 Review.

7

Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.

Creasey AA, Chang AC, Feigen L, Wün TC, Taylor FB Jr, Hinshaw LB. Creasey AA, et al. J Clin Invest. 1993 Jun;91(6):2850-60. doi: 10.1172/JCI116529. J Clin Invest. 1993. PMID: 8514893 Free PMC article.

8

Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia.

de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, van Deventer SJ, van Der Poll T. de Jonge E, et al. Among authors: creasey aa. Blood. 2000 Feb 15;95(4):1124-9. Blood. 2000. PMID: 10666180 Free article. Clinical Trial.

9

Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli.

Creasey AA, Stevens P, Kenney J, Allison AC, Warren K, Catlett R, Hinshaw L, Taylor FB Jr. Creasey AA, et al. Circ Shock. 1991 Feb;33(2):84-91. Circ Shock. 1991. PMID: 2049816

10

Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14.

Park CT, Creasey AA, Wright SD. Park CT, et al. Among authors: creasey aa. Blood. 1997 Jun 15;89(12):4268-74. Blood. 1997. PMID: 9192748 Free article.

Tissue factor pathway inhibitor (TFPI) is a Kunitz-type plasma protease inhibitor that inhibits factor Xa and the factor VIIa/tissue factor catalytic complex. ...TFPI has also been used successfully to prevent lethality and attenuate coagulopathic responses in a bab …

Tissue factor pathway inhibitor (TFPI) is a Kunitz-type plasma protease inhibitor that inhibits factor Xa and the factor VIIa/tissue …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

79 results

Search Page

Filters